, Volume 68, Issue 18, pp 2611–2632 | Cite as

Antidepressants for the Treatment of Chronic Pain

  • Bénédicte Verdu
  • Isabelle Decosterd
  • Thierry Buclin
  • Friedrich Stiefel
  • Alexandre Berney
Review Article


Chronic pain represents one of the most important public health problems and, in addition to classical analgesics, antidepressants are an essential part of the therapeutic strategy. This article reviews available evidence on the efficacy and safety of antidepressants in major chronic pain conditions; namely, neuropathic pain, headaches, low back pain, fibromyalgia, irritable bowel syndrome (IBS) and cancer pain. Studies, reviews and meta-analyses published from 1991 to March 2008 were retrieved through MEDLINE, PsycINFO and the Cochrane database using numerous key words for pain and antidepressants. In summary, evidence supports the use of tricyclic antidepressants in neuropathic pain, headaches, low back pain, fibromyalgia and IBS. The efficacy of the newer serotonin and norepinephrine reuptake inhibitors is less supported by evidence, but can be recommended in neuropathic pain, migraines and fibromyalgia. To date, evidence does not support an analgesic effect of serotonin reuptake inhibitors, but beneficial effects on well-being were reported in several chronic pain conditions. These results are discussed in the light of current insights in the neurobiology of pain, the reciprocal relationship between pain and depression, and future developments in this field of research.


Migraine Chronic Pain Neuropathic Pain Irritable Bowel Syndrome Fibromyalgia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Temugin Berta (Isabelle Decosterd’s laboratory) for the art work in figure 1. Isabelle Decosterd is supported by the Swiss National Science Foundation (grant # 112577/1) and the Pierre Mercier Science Foundation. The authors have not conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Bouhassira D. Definition and classification of neuropathic pain [in French]. Presse Med 2008; 37: 311–4PubMedCrossRefGoogle Scholar
  2. 2.
    Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999; Suppl. 6: S141–7Google Scholar
  3. 3.
    Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441–51PubMedGoogle Scholar
  4. 4.
    Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 40(18): 1630–5CrossRefGoogle Scholar
  5. 5.
    Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555–64PubMedCrossRefGoogle Scholar
  6. 6.
    Harris RE, Clauw DJ, Scott DJ, et al. Decreased central muopioid receptor availability in fibromyalgia. J Neurosci 2007; 27: 10000–6PubMedCrossRefGoogle Scholar
  7. 7.
    Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48: 1420–9PubMedCrossRefGoogle Scholar
  8. 8.
    Banic B, Petersen-Felix S, Andersen OK, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004; 107: 7–15PubMedCrossRefGoogle Scholar
  9. 9.
    Stiefel F. Psychosocial aspects of cancer pain. Support Care Cancer 1993; 1: 130–4PubMedCrossRefGoogle Scholar
  10. 10.
    Stiefel F, Stagno D. Management of insomnia in patients with chronic pain conditions. CNS Drugs 2004; 18: 285–96PubMedCrossRefGoogle Scholar
  11. 11.
    Merskey H, Bogduk N. International Association for the Study of Pain (IASP). Task force on taxonomy: classification of chronic pain. Seattle (WA): IASP Press, 1994Google Scholar
  12. 12.
    Woolf CJ, Ma Q. Nociceptors-noxious stimulus detectors. Neuron 2007; 55: 353–64PubMedCrossRefGoogle Scholar
  13. 13.
    Cummins TR, Sheets PL, Waxman SG. The roles of sodium Channels in nociception: implications for mechanisms of pain. Pain 2007; 131: 243–57PubMedCrossRefGoogle Scholar
  14. 14.
    Ignatowski TA, Sud R, Reynolds JL, et al. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). Neuropharmacology 2005; 48: 448–60PubMedCrossRefGoogle Scholar
  15. 15.
    Mico JA, Ardid D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348–54PubMedCrossRefGoogle Scholar
  16. 16.
    Yaron I, Shirazi I, Judovich R, et al. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42: 2561–8PubMedCrossRefGoogle Scholar
  17. 17.
    Berta T, Poirot O, Pertin M, et al. Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol Cell Neurosci 2008; 37: 196–208PubMedCrossRefGoogle Scholar
  18. 18.
    Pertin M, Ji RR, Berta T, et al. Upregulation of the voltage-gated sodium channel beta2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci 2005; 25: 10970–80PubMedCrossRefGoogle Scholar
  19. 19.
    Brau ME, Dreimann M, Olschewski A, et al. Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons. Anesthesiology 2001; 94: 137–44PubMedCrossRefGoogle Scholar
  20. 20.
    Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305PubMedCrossRefGoogle Scholar
  21. 21.
    Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399–409PubMedCrossRefGoogle Scholar
  22. 22.
    Song JH, Ham SS, Shin YK, et al. Amitriptyline modulation of Na(+) channels in rat dorsal root ganglion neurons. Eur J Pharmacol 2000; 401: 297–305PubMedCrossRefGoogle Scholar
  23. 23.
    Wang GK, Russell C, Wang SY. State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004; 110: 166–74PubMedCrossRefGoogle Scholar
  24. 24.
    Pancrazio JJ, Kamatchi GL, Roscoe AK, et al. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284: 208–14PubMedGoogle Scholar
  25. 25.
    Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 1996; 220: 117–20PubMedCrossRefGoogle Scholar
  26. 26.
    Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; 291: 280–4PubMedGoogle Scholar
  27. 27.
    Sudoh Y, Cahoon EE, Gerner P, et al. Tricyclic antidepressants as long-acting local anesthetics. Pain 2003; 103: 49–55PubMedCrossRefGoogle Scholar
  28. 28.
    Apkarian AV, Bushneil MC, Treede RD, et al. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005; 9: 463–84PubMedCrossRefGoogle Scholar
  29. 29.
    Neugebauer V, Li W, Bird GC, et al. The amygdala and persistent pain. Neuroscientist 2004; 10: 221–34PubMedCrossRefGoogle Scholar
  30. 30.
    Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007; 55: 377–91PubMedCrossRefGoogle Scholar
  31. 31.
    Zhao MG, Ko SW, Wu LJ, et al. Enhanced presynaptic neuro-transmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci 2006; 26: 8923–30PubMedCrossRefGoogle Scholar
  32. 32.
    Zhuo M. Molecular mechanisms of pain in the anterior cingulate cortex. J Neurosci Res 2006; 84: 927–33PubMedCrossRefGoogle Scholar
  33. 33.
    Baliki MN, Geha PY, Apkarian AV, et al. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci 2008; 28: 1398–403PubMedCrossRefGoogle Scholar
  34. 34.
    Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6: 545–52PubMedCrossRefGoogle Scholar
  35. 35.
    Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355–474PubMedCrossRefGoogle Scholar
  36. 36.
    Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002; 25: 319–25PubMedCrossRefGoogle Scholar
  37. 37.
    Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998; 124: 669–74PubMedCrossRefGoogle Scholar
  38. 38.
    Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999; 273: 85–8PubMedCrossRefGoogle Scholar
  39. 39.
    Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects: a possible opioid involvement in severe depression? J Mol Neurosci 2002; 18: 143–9PubMedCrossRefGoogle Scholar
  40. 40.
    Lavoie PA, Beauchamp G, Elie R. Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na(+)-Ca2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol 1990; 68: 1414–8PubMedCrossRefGoogle Scholar
  41. 41.
    Lavoie PA, Beauchamp G, Elie R. Atypical antidepressants inhibit depolarization-induced calcium uptake in rat hippocampus synaptosomes. Can J Physiol Pharmacol 1997; 75: 983–7PubMedCrossRefGoogle Scholar
  42. 42.
    Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686–8PubMedCrossRefGoogle Scholar
  43. 43.
    Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007; 10: 1361–8PubMedCrossRefGoogle Scholar
  44. 44.
    Wen YR, Suter MR, Kawasaki Y, et al. Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 2007; 107: 312–21PubMedCrossRefGoogle Scholar
  45. 45.
    Zhuang ZY, Wen YR, Zhang DR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006; 26: 3551–60PubMedCrossRefGoogle Scholar
  46. 46.
    Scholz J, Broom DC, Youn DH, et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005; 25: 7317–23PubMedCrossRefGoogle Scholar
  47. 47.
    Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995; 83: 1046–54PubMedCrossRefGoogle Scholar
  48. 48.
    Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. Eur J Pharmacol 2001; 429: 1–11PubMedCrossRefGoogle Scholar
  49. 49.
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; (4): CD005454Google Scholar
  50. 50.
    Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327–31PubMedCrossRefGoogle Scholar
  51. 51.
    Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96: 365–73PubMedCrossRefGoogle Scholar
  52. 52.
    Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. BMJ (Clin Res Ed) 1984; 288: 436–8CrossRefGoogle Scholar
  53. 53.
    Gomez-Perez FJ, Rull JA, Dies H, et al. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: a double-blind cross-over study. Pain 1985; 23: 395–400PubMedCrossRefGoogle Scholar
  54. 54.
    Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188–92PubMedCrossRefGoogle Scholar
  55. 55.
    Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51: 1682–8Google Scholar
  56. 56.
    Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47: 305–12PubMedCrossRefGoogle Scholar
  57. 57.
    Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251: 1727–30PubMedCrossRefGoogle Scholar
  58. 58.
    Lampl C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central poststroke pain: preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002; 33: 3030–2PubMedCrossRefGoogle Scholar
  59. 59.
    Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27–36PubMedCrossRefGoogle Scholar
  60. 60.
    Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589–96PubMedCrossRefGoogle Scholar
  61. 61.
    Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32PubMedCrossRefGoogle Scholar
  62. 62.
    Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3–9PubMedCrossRefGoogle Scholar
  63. 63.
    McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 2000; 49: 574–9PubMedCrossRefGoogle Scholar
  64. 64.
    Mercadante S, Arcuri E, Tirelli W, et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 2002; 88: 239–42PubMedGoogle Scholar
  65. 65.
    Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990; 82: 34–8PubMedCrossRefGoogle Scholar
  66. 66.
    Pilowsky I, Hallett EC, Bassett DL, et al. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982; 14: 169–79PubMedCrossRefGoogle Scholar
  67. 67.
    Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015–21PubMedCrossRefGoogle Scholar
  68. 68.
    Robinson LR, Czerniecki JM, Ehde DM, et al. Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Arch Phys Med Rehabil 2004; 85: 1–6PubMedGoogle Scholar
  69. 69.
    Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697–706PubMedCrossRefGoogle Scholar
  70. 70.
    Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280: 1590–5Google Scholar
  71. 71.
    Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151–3PubMedCrossRefGoogle Scholar
  72. 72.
    Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683–91PubMedCrossRefGoogle Scholar
  73. 73.
    Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135–44PubMedCrossRefGoogle Scholar
  74. 74.
    Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251–5PubMedCrossRefGoogle Scholar
  75. 75.
    Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284–9PubMedCrossRefGoogle Scholar
  76. 76.
    Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980; 243: 1147–50PubMedCrossRefGoogle Scholar
  77. 77.
    Vrethem M, Boivie J, Arnqvist H, et al. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997; 13: 313–23PubMedCrossRefGoogle Scholar
  78. 78.
    Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671–3PubMedCrossRefGoogle Scholar
  79. 79.
    Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. Int J Neurosci 1979; 9: 191–4PubMedCrossRefGoogle Scholar
  80. 80.
    Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250–6PubMedCrossRefGoogle Scholar
  81. 81.
    Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain 1992; 48: 29–36PubMedCrossRefGoogle Scholar
  82. 82.
    Ventafridda V, Bonezzi C, Caraceni A, et al. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Ital J Neurol Sci 1987; 8: 579–87PubMedCrossRefGoogle Scholar
  83. 83.
    Gobel H, Stadler T. Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine [in French]. Drugs 1997; 53 Suppl. 2: 34–9Google Scholar
  84. 84.
    Langohr HD, Stohr M, Petruch F. An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies. Eur Neurol 1982; 21: 309–17PubMedCrossRefGoogle Scholar
  85. 85.
    Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995; 12: 111–20PubMedGoogle Scholar
  86. 86.
    Hampf G, Bowsher D, Nurmikko T. Distigmine and amitriptyline in the treatment of chronic pain. Anesth Prog 1989; 36: 58–62PubMedGoogle Scholar
  87. 87.
    Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20: 280–5PubMedCrossRefGoogle Scholar
  88. 88.
    Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931–7PubMedCrossRefGoogle Scholar
  89. 89.
    Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166–71PubMedCrossRefGoogle Scholar
  90. 90.
    Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J 1977; 53 Suppl. 4: 104–9Google Scholar
  91. 91.
    Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64: 293–302PubMedCrossRefGoogle Scholar
  92. 92.
    Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptyline-fluphenazine vs carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525–9PubMedGoogle Scholar
  93. 93.
    Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547–52PubMedCrossRefGoogle Scholar
  94. 94.
    Maina G, Vitalucci A, Gandolfo S, et al. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002; 63: 38–43PubMedCrossRefGoogle Scholar
  95. 95.
    Ciaramella A, Grosso S, Poli P. Fluoxetine versus fluvoxamine for treatment of chronic pain [in Italian]. Minerva Anestesiol 2000; 66: 55–61PubMedGoogle Scholar
  96. 96.
    Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18: 131–7PubMedGoogle Scholar
  97. 97.
    Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004; 27: 133–9PubMedCrossRefGoogle Scholar
  98. 98.
    Yucel A, Ozyalcin S, Koknel TG, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005; 9: 407–16PubMedCrossRefGoogle Scholar
  99. 99.
    Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6: 17–24PubMedCrossRefGoogle Scholar
  100. 100.
    Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–18PubMedCrossRefGoogle Scholar
  101. 101.
    Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346–56PubMedCrossRefGoogle Scholar
  102. 102.
    Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411–20PubMedCrossRefGoogle Scholar
  103. 103.
    Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007; 29 Suppl.: 2536–46PubMedCrossRefGoogle Scholar
  104. 104.
    Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305PubMedCrossRefGoogle Scholar
  105. 105.
    Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153–69PubMedCrossRefGoogle Scholar
  106. 106.
    Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98: 195–203PubMedCrossRefGoogle Scholar
  107. 107.
    Kautio AL, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35: 31–9PubMedCrossRefGoogle Scholar
  108. 108.
    Tomkins GE, Jackson JL, O’Malley PG, et al. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111: 54–63PubMedCrossRefGoogle Scholar
  109. 109.
    Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964; I: 1236–9CrossRefGoogle Scholar
  110. 110.
    Diamond S, Baltes BJ. Chronic tension headache treated with amitriptyline: a double-blind study. Headache 1971; 11: 110–6PubMedCrossRefGoogle Scholar
  111. 111.
    Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35: 500–4PubMedCrossRefGoogle Scholar
  112. 112.
    Okasha A, Ghaleb HA, Sadek A. A double blind trial for the clinical management of psychogenic headache. Br J Psychiatry 1973; 122: 181–3PubMedCrossRefGoogle Scholar
  113. 113.
    Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695–9PubMedCrossRefGoogle Scholar
  114. 114.
    Morland TJ, Storli OV, Mogstad TE. Doxepin in the prophylactic treatment of mixed ‘vascular’ and tension headache. Headache 1979; 19: 382–3PubMedCrossRefGoogle Scholar
  115. 115.
    Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8 Suppl. 3: 49–52Google Scholar
  116. 116.
    Fogelholm R, Murros K. Maprotiline in chronic tension headache: a double-blind cross-over study. Headache 1985; 25: 273–5PubMedCrossRefGoogle Scholar
  117. 117.
    Langemark M, Loldrup D, Bech P, et al. Clomipramine and mianserin in the treatment of chronic tension headache: a double-blind, controlled study. Headache 1990; 30: 118–21PubMedCrossRefGoogle Scholar
  118. 118.
    Gobel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59: 241–9PubMedCrossRefGoogle Scholar
  119. 119.
    Pfaffenrath V, Diener HC, Isler H, et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension-type headache: a multi-centre controlled study. Cephalalgia 1994; 14: 149–55PubMedCrossRefGoogle Scholar
  120. 120.
    Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61: 285–90PubMedCrossRefGoogle Scholar
  121. 121.
    Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol 1987; 44: 486–9PubMedCrossRefGoogle Scholar
  122. 122.
    Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson’s disease: a double-blind placebo-controlled study. Neurology 1988; 38: 1720–2PubMedCrossRefGoogle Scholar
  123. 123.
    Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36: 684–90PubMedCrossRefGoogle Scholar
  124. 124.
    Mathew NT. Prophylaxis of migraine and mixed headache: a randomized controlled study. Headache 1981; 21: 105–9PubMedCrossRefGoogle Scholar
  125. 125.
    Langohr HD, Gerber WD, Koletzki E, et al. Clomipramine and metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1985; 25: 107–13PubMedCrossRefGoogle Scholar
  126. 126.
    Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust 1968; 1: 54–5PubMedGoogle Scholar
  127. 127.
    Sjaastad O, Stensrud P. Appraisal of BC-105 in migraine prophylaxis. Acta Neurol Scand 1969; 45: 594–600PubMedCrossRefGoogle Scholar
  128. 128.
    Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. N Z Med J 1971; 73: 5–9PubMedGoogle Scholar
  129. 129.
    Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res Clin Exp 1971; 13: 63–8PubMedGoogle Scholar
  130. 130.
    Ryan RE. BC-105 a new preparation for the interval treatment of migraine: a double blind evaluation compared with a placebo. Headache 1971; 11: 6–18PubMedCrossRefGoogle Scholar
  131. 131.
    Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Opin 1975; 3: 68–71PubMedCrossRefGoogle Scholar
  132. 132.
    Heathfield KW, Stone P, Crowder D. Pizotifen in the treatment of migraine. Practitioner 1977; 218: 428–30PubMedGoogle Scholar
  133. 133.
    Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache 1977; 17: 109–12PubMedCrossRefGoogle Scholar
  134. 134.
    Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo- (Divascan) in migraine prophylaxis. Acta Neurol Scand 1977; 56: 17–28PubMedCrossRefGoogle Scholar
  135. 135.
    Kangasniemi P. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. Headache 1979; 19: 219–22PubMedCrossRefGoogle Scholar
  136. 136.
    Denaro A, Martucci N, Ruggieri S, et al. Headache and nor-adrenergic involvement: the effects of alpha 2-stimulants and alpha 2-antagonists. Acta Psychiatr Scand Suppl 1985; 320: 20–5PubMedCrossRefGoogle Scholar
  137. 137.
    Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand Suppl 1985; 320: 98–103PubMedCrossRefGoogle Scholar
  138. 138.
    Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710–5PubMedCrossRefGoogle Scholar
  139. 139.
    Cleland PG, Barnes D, Elrington GM, et al. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997; 38: 31–8PubMedCrossRefGoogle Scholar
  140. 140.
    Bademosi O, Osuntokun BO. Pizotifen in the management of migraine. Practitioner 1978; 220: 325–7PubMedGoogle Scholar
  141. 141.
    Zeeberg I, Orholm M, Nielsen JD, et al. Femoxetine in the prophylaxis of migraine: a randomised comparison with placebo. Acta Neurol Scand 1981; 64: 452–9PubMedCrossRefGoogle Scholar
  142. 142.
    Sjaastad O. So-called “tension headache”. The response to a 5-HT uptake inhibitor: femoxetine. Cephalalgia 1983; 3: 53–60Google Scholar
  143. 143.
    Orholm M, Honore PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand 1986; 74: 235–9PubMedCrossRefGoogle Scholar
  144. 144.
    Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32: 101–4PubMedCrossRefGoogle Scholar
  145. 145.
    Manna V, Bolino F, Di CL. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994; 34: 44–9PubMedCrossRefGoogle Scholar
  146. 146.
    Saper JR, Silberstein SD, Lake III AE, et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497–502PubMedCrossRefGoogle Scholar
  147. 147.
    Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci 2006; 27: 410–5PubMedCrossRefGoogle Scholar
  148. 148.
    Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006; 23: 461–89PubMedCrossRefGoogle Scholar
  149. 149.
    Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919Google Scholar
  150. 150.
    d’Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39: 716–9PubMedCrossRefGoogle Scholar
  151. 151.
    Steiner TJ, Ahmed F, Findley LJ, et al. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283–6PubMedCrossRefGoogle Scholar
  152. 152.
    Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39: 28–32PubMedCrossRefGoogle Scholar
  153. 153.
    Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34: 476–8PubMedCrossRefGoogle Scholar
  154. 154.
    Oguzhanoglu A, Sahiner T, Kurt T, et al. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999; 19: 531–2PubMedCrossRefGoogle Scholar
  155. 155.
    Walker Z, Walker RW, Robertson MM, et al. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine. Headache 1998; 38: 523–8PubMedCrossRefGoogle Scholar
  156. 156.
    Langemark M, Bach FW, Jensen TS, et al. Decreased nociceptive flexion reflex threshold in chronic tension-type headache. Arch Neurol 1993; 50: 1061–4PubMedCrossRefGoogle Scholar
  157. 157.
    Krymchantowski AV, Silva MT, Barbosa JS, et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002; 42: 510–4PubMedCrossRefGoogle Scholar
  158. 158.
    Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62: 1706–11PubMedCrossRefGoogle Scholar
  159. 159.
    Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107: 44–8PubMedCrossRefGoogle Scholar
  160. 160.
    Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144–52PubMedCrossRefGoogle Scholar
  161. 161.
    Cassidy JD, Carroll LJ, Cote P. The Saskatchewan health and back pain survey: the prevalence of low back pain and related disability in Saskatchewan adults. Spine 1998; 23: 1860–6PubMedCrossRefGoogle Scholar
  162. 162.
    Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med 2002; 162: 19–24PubMedCrossRefGoogle Scholar
  163. 163.
    Staiger TO, Gaster B, Sullivan MD, et al. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003; 28: 2540–5PubMedCrossRefGoogle Scholar
  164. 164.
    Katz J, Pennella-Vaughan J, Hetzel RD, et al. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 2005; 6: 656–61PubMedCrossRefGoogle Scholar
  165. 165.
    Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res 1976; 4: 28–40PubMedGoogle Scholar
  166. 166.
    Alcoff J, Jones E, Rust P, et al. Controlled trial of imipramine for chronic low back pain. J Fam Pract 1982; 14: 841–6PubMedGoogle Scholar
  167. 167.
    Ward N, Bokan JA, Phillips M, et al. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J Clin Psychiatry 1984; 45: 54–9PubMedGoogle Scholar
  168. 168.
    Hameroff SR, Weiss JL, Lerman JC, et al. Doxepin’s effects on chronic pain and depression: a controlled study. J Clin Psychiatry 1984; 45: 47–53PubMedGoogle Scholar
  169. 169.
    Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998; 76: 287–96PubMedCrossRefGoogle Scholar
  170. 170.
    Pheasant H, Bursk A, Goldfarb J, et al. Amitriptyline and chronic low-back pain: a randomized double-blind crossover study. Spine 1983; 8: 552–7PubMedCrossRefGoogle Scholar
  171. 171.
    Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of nor-adrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999; 83: 137–45PubMedCrossRefGoogle Scholar
  172. 172.
    Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol 1990; 10: 269–78PubMedCrossRefGoogle Scholar
  173. 173.
    Dickens C, Jayson M, Sutton C, et al. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics 2000; 41: 490–9PubMedCrossRefGoogle Scholar
  174. 174.
    Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505–14PubMedGoogle Scholar
  175. 175.
    Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72PubMedCrossRefGoogle Scholar
  176. 176.
    Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–9PubMedGoogle Scholar
  177. 177.
    Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846–50PubMedGoogle Scholar
  178. 178.
    Arnold LM, Keck Jr PE, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000; 41: 104–13PubMedCrossRefGoogle Scholar
  179. 179.
    O’Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000; 15: 659–66PubMedCrossRefGoogle Scholar
  180. 180.
    Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 1986; 29: 655–9PubMedCrossRefGoogle Scholar
  181. 181.
    Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987; 15: 154–9PubMedGoogle Scholar
  182. 182.
    Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum 1988; 31: 1535–42PubMedCrossRefGoogle Scholar
  183. 183.
    Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989; 19: 140–3PubMedGoogle Scholar
  184. 184.
    Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38: 1211–7PubMedCrossRefGoogle Scholar
  185. 185.
    Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991; 18: 452–4PubMedGoogle Scholar
  186. 186.
    Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292: 2388–95PubMedCrossRefGoogle Scholar
  187. 187.
    Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994; 37: 32–40Google Scholar
  188. 188.
    Scudds RA, McCain GA, Rollman GB, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989; 19: 98–103PubMedGoogle Scholar
  189. 189.
    Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37: 1279–86PubMedCrossRefGoogle Scholar
  190. 190.
    Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29: 1371–7PubMedCrossRefGoogle Scholar
  191. 191.
    Kempenaers C, Simenon G, Vander EM, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 1994; 30: 66–72PubMedCrossRefGoogle Scholar
  192. 192.
    Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61: 445–9PubMedCrossRefGoogle Scholar
  193. 193.
    Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23: 255–9PubMedCrossRefGoogle Scholar
  194. 194.
    Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852–9PubMedCrossRefGoogle Scholar
  195. 195.
    Tavoni A, Vitali C, Bombardiert S, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. Am J Med 1987; 83: 107–10PubMedCrossRefGoogle Scholar
  196. 196.
    Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991; 20: 294–302PubMedCrossRefGoogle Scholar
  197. 197.
    Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112: 191–7PubMedCrossRefGoogle Scholar
  198. 198.
    Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975–85PubMedGoogle Scholar
  199. 199.
    Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–84PubMedCrossRefGoogle Scholar
  200. 200.
    Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15PubMedCrossRefGoogle Scholar
  201. 201.
    Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432–44PubMedCrossRefGoogle Scholar
  202. 202.
    Rooks DS. Fibromyalgia treatment update. Curr Opin Rheumatol 2007; 19: 111–7PubMedGoogle Scholar
  203. 203.
    Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62 Suppl. 8: 38–45PubMedGoogle Scholar
  204. 204.
    Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65–72PubMedCrossRefGoogle Scholar
  205. 205.
    Loldrup D, Langemark M, Hansen HJ, et al. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology (Berl) 1989; 99: 1–7CrossRefGoogle Scholar
  206. 206.
    Myren J, Lovland B, Larssen SE, et al. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 835–43PubMedGoogle Scholar
  207. 207.
    Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160–5PubMedCrossRefGoogle Scholar
  208. 208.
    Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics 1978; 19: 540–7PubMedGoogle Scholar
  209. 209.
    Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome (double blind randomised study). J Assoc Physicians India 1983; 31: 201–3PubMedGoogle Scholar
  210. 210.
    Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 257–66PubMedCrossRefGoogle Scholar
  211. 211.
    Myren J, Groth H, Larssen SE, et al. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. Scand J Gastroenterol 1982; 17: 871–5PubMedCrossRefGoogle Scholar
  212. 212.
    Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med 1981; 11: 45–57PubMedCrossRefGoogle Scholar
  213. 213.
    Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738–41PubMedCrossRefGoogle Scholar
  214. 214.
    Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31: 318–25PubMedCrossRefGoogle Scholar
  215. 215.
    Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; (2): CD003460Google Scholar
  216. 216.
    Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219–28PubMedCrossRefGoogle Scholar
  217. 217.
    Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99: 914–20PubMedCrossRefGoogle Scholar
  218. 218.
    Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095–103PubMedCrossRefGoogle Scholar
  219. 219.
    Creed F. How do SSRIs help patients with irritable bowel syndrome? Gut 2006; 55: 1065–7PubMedCrossRefGoogle Scholar
  220. 220.
    Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93: 247–57PubMedCrossRefGoogle Scholar
  221. 221.
    Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7: 797–809PubMedCrossRefGoogle Scholar
  222. 222.
    Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9: 571–91PubMedCrossRefGoogle Scholar
  223. 223.
    Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage 1999; 18: 358–68PubMedCrossRefGoogle Scholar
  224. 224.
    Sjogren P, Banning AM, Jensen NH, et al. Management of cancer pain in Denmark: a nationwide questionnaire survey. Pain 1996; 64: 519–25PubMedCrossRefGoogle Scholar
  225. 225.
    McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003; 106: 127–33PubMedCrossRefGoogle Scholar
  226. 226.
    McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111: 77–83PubMedCrossRefGoogle Scholar
  227. 227.
    Von KM, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. Pain 2005; 113: 331–9CrossRefGoogle Scholar
  228. 228.
    Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993; 150: 734–41PubMedGoogle Scholar
  229. 229.
    Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003; 60: 39–47PubMedCrossRefGoogle Scholar
  230. 230.
    Husain MM, Rush AJ, Trivedi MH, et al. Pain in depression: STAR*D study findings. J Psychosom Res 2007; 63: 113–22PubMedCrossRefGoogle Scholar
  231. 231.
    Hudson JI, Hudson MS, Pliner LF, et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985; 142: 441–6PubMedGoogle Scholar
  232. 232.
    Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain 2004; 107: 54–60PubMedCrossRefGoogle Scholar
  233. 233.
    Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63: 35–41PubMedCrossRefGoogle Scholar
  234. 234.
    Magni G, Moreschi C, Rigatti-Luchini S, et al. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 1994; 56: 289–97PubMedCrossRefGoogle Scholar
  235. 235.
    Larson SL, Clark MR, Eaton WW. Depressive disorder as a long-term antecedent risk factor for incident back pain: a 13-year follow-up study from the Baltimore Epidemiological Catchment Area sample. Psychol Med 2004; 34: 211–9PubMedCrossRefGoogle Scholar
  236. 236.
    Pine DS, Cohen P, Brook J. The association between major depression and headache: results of a longitudinal epidemiologic study in youth. J Child Adolesc Psychopharmacol 1996; 6: 153–64PubMedCrossRefGoogle Scholar
  237. 237.
    Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45PubMedCrossRefGoogle Scholar
  238. 238.
    Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 2004; 19 Suppl. 1: S3–7PubMedCrossRefGoogle Scholar
  239. 239.
    Dersh J, Gatchel RJ, Polatin P, et al. Prevalence of psychiatric disorders in patients with chronic work-related musculoskeletal pain disability. J Occup Environ Med 2002; 44: 459–68PubMedCrossRefGoogle Scholar
  240. 240.
    Burns JW, Johnson BJ, Mahoney N, et al. Cognitive and physical capacity process variables predict long-term outcome after treatment of chronic pain. J Consult Clin Psychol 1998; 66: 434–9PubMedCrossRefGoogle Scholar
  241. 241.
    Lin EH, Katon W, Von KM, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 2003; 290: 2428–9PubMedCrossRefGoogle Scholar
  242. 242.
    Fishbain DA. The association of chronic pain and suicide. Semin Clin Neuropsychiatry 1999; 4: 221–7PubMedGoogle Scholar
  243. 243.
    Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001; 26: 37–43PubMedGoogle Scholar
  244. 244.
    Berney A, Nishikawa M, Benkelfat C, et al. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[HC]methyl-L-tryptophan PET study. Neurochem Int 2008; 52: 701–8PubMedCrossRefGoogle Scholar
  245. 245.
    Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 30–6PubMedGoogle Scholar
  246. 246.
    Perrot S, Maheu E, Javier RM, et al. Guidelines for the use of antidepressants in painful rheumatic conditions. Eur J Pain 2006; 10: 185–92PubMedCrossRefGoogle Scholar
  247. 247.
    Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1547–60PubMedCrossRefGoogle Scholar
  248. 248.
    Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol Sci 2004; 25 Suppl. 3: S171–5PubMedCrossRefGoogle Scholar
  249. 249.
    Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58–77PubMedCrossRefGoogle Scholar
  250. 250.
    Chutka DS. Cardiovascular effects of the antidepressants: recognition and control. Geriatrics 1990; 45: 55–9, 62, 67PubMedGoogle Scholar
  251. 251.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112–20PubMedCrossRefGoogle Scholar
  252. 252.
    Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39: 43–53PubMedCrossRefGoogle Scholar
  253. 253.
    Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007; 68: 1707–16PubMedCrossRefGoogle Scholar
  254. 254.
    Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006; 51: 300–16PubMedGoogle Scholar
  255. 255.
    Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58: 291–7PubMedCrossRefGoogle Scholar
  256. 256.
    Mayr BJ, Bonelli RM. Severe headache with venlafaxine withdrawal. Ann Pharmacother 2003; 37: 1145–6PubMedCrossRefGoogle Scholar
  257. 257.
    Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007; 82: 606–9PubMedCrossRefGoogle Scholar
  258. 258.
    Kirchheiner J, Seeringer A. Clinical implications of pharmaco-genetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770: 489–94PubMedCrossRefGoogle Scholar
  259. 259.
    Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75: 386–93PubMedCrossRefGoogle Scholar
  260. 260.
    McAlpine DE, O’Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007; 82: 1065–8PubMedCrossRefGoogle Scholar
  261. 261.
    Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899–902PubMedCrossRefGoogle Scholar
  262. 262.
    Ereshefsky L, Jhee S, Grothe D. Antidepressant drug-drug interaction profile update. Drugs R D 2005; 6: 323–36PubMedCrossRefGoogle Scholar
  263. 263.
    Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9PubMedCrossRefGoogle Scholar
  264. 264.
    Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77: 312–23PubMedCrossRefGoogle Scholar
  265. 265.
    Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29 Suppl.: 2477–97PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Bénédicte Verdu
    • 1
  • Isabelle Decosterd
    • 2
    • 3
  • Thierry Buclin
    • 4
  • Friedrich Stiefel
    • 1
  • Alexandre Berney
    • 1
  1. 1.Department of PsychiatryUniversity Hospital Center and University of LausanneLausanneSwitzerland
  2. 2.Pain Research Unit, Department of AnesthesiologyUniversity Hospital Center and University of LausanneLausanneSwitzerland
  3. 3.Department of Cell Biology and MorphologyUniversity Hospital Center and University of LausanneLausanneSwitzerland
  4. 4.Division of Clinical Pharmacology and ToxicologyUniversity Hospital Center and University of LausanneLausanneSwitzerland

Personalised recommendations